fulvestrant has been researched along with Anemia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Augereau, P; Campion, L; Campone, M; Caroline, F; du Rusquec, P; Dumas, L; Frenel, JS; Gourmelon, C; Palpacuer, C; Patsouris, A; Robert, M | 1 |
| Al-Qaisi, A; Awasthi, M; Chen, A; Chen, L; Kadamyan-Melkumyan, V; Massarweh, S; Romond, E | 1 |
1 trial(s) available for fulvestrant and Anemia
| Article | Year |
|---|---|
Everolimus-induced hematologic changes in patients with metastatic breast cancer.
Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Erythrocyte Count; Erythrocyte Indices; Estradiol; Everolimus; Female; Fulvestrant; Hematologic Diseases; Humans; Leukocyte Count; Leukopenia; Neoplasm Metastasis; Sirolimus; Thrombocytopenia | 2015 |
1 other study(ies) available for fulvestrant and Anemia
| Article | Year |
|---|---|
Efficacy of palbociclib plus fulvestrant after everolimus in hormone receptor-positive metastatic breast cancer.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy-Induced Febrile Neutropenia; Everolimus; Female; Follow-Up Studies; Fulvestrant; Humans; Middle Aged; Piperazines; Progression-Free Survival; Pyridines; Receptors, Estrogen; Receptors, Progesterone; Thrombocytopenia | 2018 |